Synapse - Works

Results (5712)

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)

Meeting Abstract

Mato, A. R.; Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; more...
Blood (2021)

Fulltext@MSK | Save

BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)

Meeting Abstract

Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Hill, M.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
Blood (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Healthcare resource utilization and costs of patients with relapsed/refractory follicular lymphoma receiving 3 or more lines of therapy

Meeting Abstract

Matasar, M. J.; Shapouri, S.; Ta, J. T.; To, T. M.; Wu, M.; Wang, R.
Blood (2021)

Fulltext@MSK | Save

Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (Measurable) residual disease (MRD)

Meeting Abstract

Koffman, B.; Stewart, C.; Avruch, L.; Bailey, N.; Brumble, R.; Byrd, J. C.; Danilov, A. V.; Davids, M. S.; Furman, R.; Jain, N.; more...
Blood (2021)

Fulltext@MSK | Save

Practice gaps and barriers in optimal care among healthcare providers treating patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): Results of a two-phase qualitative/quantitative study

Meeting Abstract

Becker, M. N.; Howson, A.; Quill, T. A.; Daver, N.; Stein, E. M.
Blood (2021)

Fulltext@MSK | Save

Post-transplant cyclophosphamide is associated with improved clinical outcomes in HLA-mismatched unrelated donor hematopoietic cell transplantation

Meeting Abstract

Jimenez, A. M.; Perales, M. A.; Devlin, S. M.; Lekakis, L. J.; Sauter, C. S.; Pereira, D.; Beitinjaneh, A.; Brown, S.; Wang, T.; Ponce, D. M.; more...
Blood (2021)

Fulltext@MSK | Save

Whole transcriptome analysis identifies distinct gene expression profiles between SF3B1(mut) and SF3B1(wt) myelodysplastic syndrome with ring sideroblasts

Meeting Abstract

Todisco, G.; Creignou, M.; Bernard, E.; Björklund, A. C.; Moura, P. L.; Jansson, M.; Chang, D.; Venckute, S.; Walldin, G.; Malcovati, L.; more...
Blood (2021)

Fulltext@MSK | Save

Clinical experience in the randomized phase 3 Sierra Trial: Anti-CD45 iodine ((131)I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed/refractory AML not responding to targeted therapies

Meeting Abstract

Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Koshy, N. V.; Stiff, P.; Abboud, C. Sr; Tomlinson, B.; Abhyankar, S.; more...
Blood (2021)

Fulltext@MSK | Save

Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy

Meeting Abstract

Yuan, X.; Clarke, R.; Lai, Y. S.; Chang, C. W.; Yang, B. H.; Hsia, G.; Abujarour, R.; Lee, T.; van der Stegen, S.; Shaked, H.; more...
Blood (2021)

Fulltext@MSK | Save